Alumis Launches $300M ATM Program, Details Recent $324M Public Offering and FY2025 Financials

summarizeSummary

Alumis Inc. announced a new $300 million ATM program and detailed a recent $324.4 million public offering, significantly strengthening its cash position to fund ongoing R&D and prepare for the planned H2 2026 NDA submission for its lead candidate, envu, following positive Phase 3 results.

check_boxKey Events

• New $300 Million At-The-Market (ATM) Program Launched

  Alumis Inc. entered into a Controlled Equity Offering Sales Agreement on March 18, 2026, to sell up to $300 million of common stock from time to time through Cantor Fitzgerald & Co. This provides flexible access to capital but represents potential future dilution for shareholders.

• Completed $324.4 Million Public Offering

  The company closed a public offering on January 9, 2026, raising $324.4 million in net proceeds. This substantial capital infusion significantly boosts the company's liquidity and extends its operating runway.

• Positive Phase 3 Results for Envu in Psoriasis Confirmed

  The 10-K reiterates positive topline results from the Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib (envu) in moderate-to-severe plaque psoriasis, with an NDA submission to the FDA planned for the second half of 2026. This key pipeline progress was previously announced in Q1 2026.

• Improved Financial Performance in 2025

  Alumis reported a net loss of $243.3 million for the year ended December 31, 2025, an improvement from a $294.2 million net loss in 2024. The company also recognized a $187.9 million gain on bargain purchase related to the ACELYRIN merger.

auto_awesomeAnalysis

Alumis Inc. has significantly bolstered its financial position and outlined its capital strategy in its latest 10-K filing. The company launched a new At-The-Market (ATM) equity offering program, allowing it to sell up to $300 million of common stock from time to time. This follows a recently closed public offering on January 9, 2026, which generated $324.4 million in net proceeds. These capital raises, while dilutive, are crucial for a clinical-stage biopharmaceutical company, extending its liquidity runway to at least 12 months from the financial statement issuance date. The filing also confirms the positive topline Phase 3 results for its lead candidate, envudeucitinib (envu), in moderate-to-severe plaque psoriasis, which were previously announced in Q1 2026, with an NDA submission planned for the second half of 2026. The company reported a reduced net loss of $243.3 million in 2025, down from $294.2 million in 2024, and recognized a $187.9 million gain on bargain purchase from the ACELYRIN merger. Investors should monitor the utilization of the ATM program for potential dilution and the progress towards envu's NDA submission and commercialization.